Discounted Cash Flow (DCF) Analysis Unlevered
Rain Oncology Inc. (RAIN)
$9.5
+0.24 (+2.59%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||
EBITDA | - | - | - | - | - | - | - | - |
EBITDA (%) | ||||||||
EBIT | - | - | - | - | - | - | - | - |
EBIT (%) | ||||||||
Depreciation | - | - | - | - | - | - | - | - |
Depreciation (%) |
Balance Sheet Data
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Total Cash | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|
Total Cash (%) | ||||||||
Account Receivables | - | - | - | - | - | - | - | - |
Account Receivables (%) | ||||||||
Inventories | - | - | - | - | - | - | - | - |
Inventories (%) | ||||||||
Accounts Payable | - | - | - | - | - | - | - | - |
Accounts Payable (%) | ||||||||
Capital Expenditure | - | - | - | - | - | - | - | - |
Capital Expenditure (%) |
Weighted Average Cost Of Capital
Share price | $ 9.5 |
---|---|
Beta | 0.000 |
Diluted Shares Outstanding | 10.66 |
Cost of Debt | |
Tax Rate | -0.00 |
After-tax Cost of Debt | 5.00% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 3.360 |
Total Debt | 0.41 |
Total Equity | 101.24 |
Total Capital | 101.65 |
Debt Weighting | 0.41 |
Equity Weighting | 99.59 |
Wacc |
Build Up Free Cash
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|
EBITDA | - | - | - | - | - | - | - | - |
EBIT | - | - | - | - | - | - | - | - |
Tax Rate | 0.00% | 0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
EBIAT | - | - | - | - | - | - | - | - |
Depreciation | - | - | - | - | - | - | - | - |
Accounts Receivable | - | - | - | - | - | - | - | - |
Inventories | - | - | - | - | - | - | - | - |
Accounts Payable | - | - | - | - | - | - | - | - |
Capital Expenditure | -0.14 | -0.02 | -2.63 | - | - | - | - | - |
UFCF | - | - | - | - | - | - | - | - |
WACC | ||||||||
PV UFCF | - | - | - | - | - | - | - | - |
SUM PV UFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 3.37 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -24.37 |
Equity Value | - |
Shares Outstanding | 10.66 |
Equity Value Per Share | - |